Sandoz Mulls At-Risk Launch For US Natalizumab

Also Provides Detailed Update On US Adalimumab And Wider Biosimilars Business

 
• By Dave Wallace
  
Businessman at chalkboard considers risk - yes or no?
Sandoz is considering whether to launch its Tyruko natalizumab biosimilar ‘at risk’ in the US • Source: Shutterstock

More from Biosimilars

More from Products